NCT03923556View on ClinicalTrials.gov

Sugammadex Versus Neostigmine for Reversal of Neuromuscular Blockade at the End of Kidney Transplantation Surgery

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 2, 2021

Primary Completion Date

September 30, 2023

Study Completion Date

October 30, 2023

Conditions

Kidney Transplant; ComplicationsPostoperative Residual CurarizationPostoperative Residual Weakness

Interventions

DRUG

Sugammadex

Administration of Sugammadex intravenously at a dose appropriate for the reversal of neuromuscular blockade (usually 2-4 mg/kg) at the end of the surgery before tracheal extubation

DRUG

Neostigmine

Administration of Neostigmine intravenously at a dose appropriate for the reversal of neuromuscular blockade (usually 0.03-0.07 mg/kg) at the end of the surgery before tracheal extubation

Trial Locations (1)

80045

University of Colorado Hospital, Aurora

All Listed Sponsors

lead

University of Colorado, Denver

OTHER

NCT03923556 - Sugammadex Versus Neostigmine for Reversal of Neuromuscular Blockade at the End of Kidney Transplantation Surgery | Biotech Hunter | Biotech Hunter